financetom
Business
financetom
/
Business
/
Campari CEO says cutting debt ratio takes priority over M&A
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Campari CEO says cutting debt ratio takes priority over M&A
Nov 7, 2025 10:23 AM

MILAN, Nov 7 (Reuters) - Campari Chief

Executive Simon Hunt on Friday ruled out acquisitions in the

short term for the Italian spirits maker and said he was focused

instead on cutting the group's debt.

With a portfolio of more than 70 brands built over the years

through a string of acquisitions, Campari has plenty of options

to drive revenue growth, said Hunt, who took the top job in

January.

Alongside the eponymous Campari brand, the group owns names

such as Wild Turkey bourbon and Espolon tequila.

In an interview with Reuters at the group's headquarters on

the outskirts of Milan, Hunt said he aimed to bring the leverage

ratio down to around 2.5 times earnings before interest, tax,

depreciation and amortisation, from 2.9 times EBITDA at present,

a target that could be achieved partly through the disposal of

smaller brands.

"I want to get it down as quickly as possible. That, then,

gives us options and we'll look at... M&A, but it will be

selective," Hunt said.

"We are not in a hurry and the reason I say that is we have

so many opportunities within the existing portfolio," said the

CEO, citing as an example the future growth potential in the

United States for Aperol, the group's signature orange aperitif.

Hunt spoke to Reuters after Campari, which is majority owned

by Italy's Garavoglia family, held an investor day, outlining

its long-term strategy without providing new financial targets.

The group has confirmed ambitions to return to mid-to-high

single-digit revenue growth over the medium term. Hunt declined

to provide a more precise timing, citing "a huge degree of

volatility outside of our control."

Hunt said Campari, with its Aperol aperitif and

non-alcoholic drink Crodino, was well placed to benefit from new

consumer trends favouring earlier-day drinking occasions and

lower-alcohol options.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Monday.com Sees Surge in High-Value Customers, Driving Impressive First Quarter Earnings
Monday.com Sees Surge in High-Value Customers, Driving Impressive First Quarter Earnings
May 15, 2024
Monday.com Ltd ( MNDY ) reported fiscal first-quarter 2024 revenue growth of 34% Y/Y to $216.9 million, beating the analyst consensus estimate of $210.4 million.  The project management software company's adjusted EPS of $0.61 beat the analyst consensus estimate of $0.40. The stock price gained after the results. The net dollar retention rate was 110%, with the net dollar retention rate for customers with more than ten users being...
Sector Update: Consumer Stocks Edge Higher Pre-Bell Wednesday
Sector Update: Consumer Stocks Edge Higher Pre-Bell Wednesday
May 15, 2024
09:09 AM EDT, 05/15/2024 (MT Newswires) -- Consumer stocks were higher pre-bell Wednesday, with the Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.4% and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) advancing 0.9%. Dole (DOLE) was up more than 4% after it reported higher Q1 adjusted earnings and revenue. Boot Barn Holdings ( BOOT...
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth
Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth
May 15, 2024
09:11 AM EDT, 05/15/2024 (MT Newswires) -- Verrica Pharmaceuticals ( VRCA ) said Wednesday it has amended its current licensing agreement with Torii Pharmaceutical to jointly carry out a global phase 3 study of Ycanth intended to treat common warts. Under the amended terms, the two parties would equally divide the cost of the trial, while Torii would also pay...
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing
May 15, 2024
09:12 AM EDT, 05/15/2024 (MT Newswires) -- Vikki L Conway, Acting Head of Global Human Resources, on May 13, 2024, sold 15,219 shares in Teva Pharmaceutical Industries ( TEVA ) for $254,807. SEC Filing: https://www.sec.gov/Archives/edgar/data/818686/000095017024060065/xslF345X03/ownership.xml Price: 17.12, Change: +0.03, Percent Change: +0.17 ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved